Alliancebernstein Reduces Stake in Amgen

Investment firm cuts holding in pharmaceutical company by 42.8%

Mar. 17, 2026 at 7:09am

Got story updates? Submit your updates here. ›

Alliancebernstein L.P. has reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 42.8% during the third quarter, according to a recent SEC filing. The firm now owns 594,786 shares of the medical research company's stock, down from 1,039,390 shares previously.

Why it matters

Amgen is a major pharmaceutical company known for its biologic medicines used in oncology, supportive care, nephrology, bone health and cardiovascular disease. Changes in institutional ownership can signal shifts in investor sentiment and market expectations around the company.

The details

According to the 13F filing, Alliancebernstein sold 444,604 shares of Amgen stock during the third quarter. The firm now owns approximately 0.11% of Amgen, down from 0.19% previously. Other institutional investors have also modified their Amgen holdings, with Lazard Asset Management LLC increasing its stake by 102.2% and New England Asset Management Inc. adding 105 shares.

  • Alliancebernstein reduced its Amgen stake during the third quarter of 2026.

The players

Alliancebernstein L.P.

A global investment management firm that provides a range of investment solutions to institutional and individual investors.

Amgen Inc.

A global biotechnology company that discovers, develops, manufactures and delivers human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Alliancebernstein's Amgen holdings reflects broader shifts in institutional ownership of the pharmaceutical company, which could signal changing market perceptions around Amgen's growth prospects and competitive positioning.